hyqvia 100mg/ml solution for infusion
baxalta innovations gmbh, austria - human normal immunoglobulin - solution for infusion - 10 %
hyqvia 100mg/ml solution for infusion
baxalta innovations gmbh, austria - human normal immunoglobulin - solution for infusion - 10 %
hyqvia 100mg/ml solution for infusion
baxalta innovations gmbh, austria - human normal immunoglobulin - solution for infusion - 10 %
hyqvia 100mg/ml solution for infusion
baxalta innovations gmbh, austria - human normal immunoglobulin - solution for infusion - 10 %
hyqvia 100mg/ml solution for infusion
baxalta innovations gmbh, austria - human normal immunoglobulin - solution for infusion - 10 %
cuvitru 200mg/ml injection solution for injection
baxalta innovations gmbh, austria - human normal immunoglobulin - solution for injection - 200 mg/ml
cuvitru 200mg/ml injection solution for injection
baxalta innovations gmbh, austria - human normal immunoglobulin - solution for injection - 200 mg/ml
cuvitru 200mg/ml injection solution for injection
baxalta innovations gmbh, austria - human normal immunoglobulin - solution for injection - 200 mg/ml
cuvitru 200mg/ml injection solution for injection
baxalta innovations gmbh, austria - human normal immunoglobulin - solution for injection - 200 mg/ml
oncaspar
baxalta innovations gmbh - pegaspargase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents, - oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years, and adult patients.,